B. Metzler seel. Sohn & Co. Holding AG Acquires New Holdings in Edwards Lifesciences Co. (NYSE:EW)

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Edwards Lifesciences Co. (NYSE:EW) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 80,358 shares of the medical research company’s stock, valued at approximately $5,303,000.

Other large investors also recently made changes to their positions in the company. Park Avenue Securities LLC raised its position in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock valued at $2,169,000 after purchasing an additional 108 shares during the period. City State Bank lifted its position in Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after acquiring an additional 130 shares during the last quarter. Stableford Capital II LLC lifted its position in Edwards Lifesciences by 2.7% during the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after acquiring an additional 159 shares during the last quarter. Purus Wealth Management LLC grew its position in shares of Edwards Lifesciences by 5.2% in the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 160 shares during the last quarter. Finally, Busey Bank lifted its position in shares of Edwards Lifesciences by 1.9% during the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock worth $816,000 after purchasing an additional 165 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the company from $100.00 to $70.00 in a report on Thursday, July 25th. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $70.20 on Wednesday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market capitalization of $41.40 billion, a PE ratio of 10.13, a PEG ratio of 3.81 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock’s fifty day moving average is $67.59 and its 200-day moving average is $75.91.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the company posted $0.59 EPS. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock worth $2,657,000 in the last quarter. Insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.